1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"NIH Director’s Early Independence Award (DP5 Clinical Trial Optional)" is currently closed and not accepting applications.
NIH Director’s Early Independence Award (DP5 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). Supports exceptional junior scientists who have the potential to become leaders in biomedical research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH Director's Early Independence Award | NIH Common Fund NIH Director's Early Independence Award NIH Director's Early Independence Award FY2025 NIH Director’s Early Independence Award informational video Part of the High-Risk, High-Reward Research program, the NIH Director's Early Independence Award supports promising, newly graduated scientists with the intellect, scientific creativity, drive, and maturity bypass the traditional postdoctoral training period to launch independent research careers.
Part of the High-Risk, High-Reward Research program , the award supports promising, newly graduated scientists with the intellect, scientific creativity, drive, and maturity to bypass the traditional postdoctoral training period to launch independent research careers.
Recipient of terminal research degree or completed postgraduate clinical training within previous 16 months or expectation to do so within following 12 months of application submission date Must be in non-independent research position at time of application submission Limit of 2 applications per institution Preliminary data not required Requires 9.
6 months of research effort each year for first 2 years Requires 3-5 Letters of Reference $250,000 direct costs per year for up to 5 years See the Award Overview for more information.
Application & Award Guide Recent News & Announcements The Rugged Landscape of Enzymes and the Future of Medicine Seeing the Whole Picture: How Multi-Omics Is Transforming Genetic Diagnosis Technological Improvements Propel Kidney Disease Research Forward NIH to award over $207 million to support highly innovative biomedical and behavioral research projects This page last reviewed on
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments. Confirm the full requirements in the official notice before applying.
The published deadline was September 11, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
NIH Director’s Early Independence Award (DP5 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article